Pralmorelin

Pralmorelin (INN) (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).

Pralmorelin
Pralmorelin
Clinical data
Other namesD-Alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide
Routes of
administration
Oral, intravenous
Identifiers
  • (2S)-6-Amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC45H55N9O6
Molar mass817.992 g·mol−1
3D model (JSmol)
  • C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N
  • InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
  • Key:HRNLPPBUBKMZMT-RDRUQFPZSA-N

Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH) and reliably induces sensations of hunger and increases food intake in humans.

Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.

See also

References

Tags:

Diagnostic agentGrowth hormone deficiencyGrowth hormone secretagogueInternational Nonproprietary NameJapanJapanese Accepted NameUnited States Adopted Name

🔥 Trending searches on Wiki English:

National Democratic AllianceAdrian NeweyAavesham (2024 film)Jill DandoThe Twist (song)TurkeyXavier WorthyMarcus AureliusMuhammadMonkey Man (film)IF (film)Patrick MahomesGmailSine and cosineLondon2024 United States presidential electionShaitaan (2024 film)Dua LipaNew York CitySam DarnoldGAZ SobolDoug Davis (businessman)Rule 34Josh O'ConnorShashank SinghRyan GarciaSalman RushdieKalanithi MaranNewJeansJodie ComerCourteney Cox2020 United States presidential electionMillie GibsonIndian Super LeagueWikipediaJC LathamIsrael–Hamas warThe Tortured Poets DepartmentDonald TrumpWorld Wide WebGuy RitchieDune (2021 film)Kool-Aid McKinstryIndiGoVarshangalkku SheshamResults of the 2019 Indian general electionRussian invasion of UkraineIndonesiaPazzi conspiracyYandexRestrictions on TikTok in the United StatesWilliam ShakespeareGhoul (Fallout)Chernobyl disasterAl PacinoCamila AlvesList of country calling codesDead Boy Detectives (TV series)Windows 10 version historyGhilliIndian National Developmental Inclusive AlliancePrince (musician)Brian Thomas Jr.George III2019 NFL draftEloy CasagrandeLeonardo DiCaprioVoyager 1Murder of Reena VirkPost MaloneAshlyn HarrisBo NixNew ZealandVoice of VietnamThe Office (American TV series)The Fall Guy (2024 film)Oppenheimer (film)Pet Shop Boys🡆 More